Benitec Biopharma Inc., a clinical-stage biotechnology company specializing in gene therapy, reported its financial results for the third fiscal quarter ending March 31, 2025. The company reported total expenses of $10.2 million for the quarter, a significant increase from $4.1 million in the same quarter of 2024. The net loss attributable to shareholders was $9.4 million, compared to a net loss of $4.3 million in the previous year's corresponding quarter. Benitec's research and development expenses, mainly associated with the clinical development of BB-301 for OPMD treatment, rose to $6 million from $2.6 million in the comparable quarter of 2024. The company's general and administrative expenses increased to $4.2 million from $1.6 million in the same period last year. As of March 31, 2025, Benitec held $103.6 million in cash and cash equivalents. The company is progressing with its clinical trials, having safely treated the final subject of Cohort 1 with a low dose of BB-301 in April 2025, and plans to enroll additional subjects at a higher dose later in the year.